GNPX) Expands Oncology R&D Pipeline to Include Small Cell Lung Cancer

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for cancer and diabetes patients, today announced that it has expanded its oncology research and development pipeline to include the small cell lung cancer (“SCLC”) as an additional indication of the disease for its lead drug candidate, REQORSA (TM) immunogenic therapy. SCLC represents approximately 10-15% of the lung cancer market, while REQORSA’s initial target indication for non-small cell lung cancer (“NSCLC”) represents approximately 84% of the lung cancer market. “Data from human studies indicate that REQORSA may be beneficial in targeting small cell lung cancer,” said Mark S. Berger, MD, medical director of Genprex. “Like non-small cell lung cancer, small cell lung cancer consistently has low levels of TUSC2 proteins and has been documented to often have an allele of the TUSC2 gene deleted. Extended stage small cell lung cancer has a very poor prognosis, with a median progression-free survival of 5.2 months. Expanding the therapeutic indications targeted by REQORSA to include small cell lung cancer may provide us with another important clinical opportunity to combine REQORSA with small cell lung cancer therapies, including checkpoint inhibitors.

To view the full press release, visit

About Genprex inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for cancer and diabetes patients. Genprex technologies are designed to deliver disease-fighting genes to deliver novel therapies to large populations of cancer and diabetes patients who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to deepen its portfolio of gene therapies in order to offer new therapeutic approaches. The company’s flagship product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer. REQORSA has a multimodal mechanism of action that interrupts cell signaling pathways that cause cancer cells to replicate and proliferate; restore the pathways of apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block the mechanisms that create drug resistance. In 2020, the United States Food and Drug Administration (“FDA”) granted Fast Track designation to REQORSA for NSCLC in combination with AstraZeneca’s Tagrisso (R) (osimertinib) for advanced patients with EFGR mutations in which tumors have progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track designation to REQORSA for NSCLC in combination therapy with Keytruda (R) from Merck & Co (pembrolizumab) for advanced patients whose disease has progressed after treatment with Keytruda. For more information, visit the company’s website at

NOTICE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements delivered in multiple languages, we’ve got the wire-quality delivery products you’ll need to make sure your next press release grabs the attention of your target audience and doesn’t let go. While our competitors seek to offer you hidden fees and restrictive word limits, InvestorWire is keeping things transparent. We offer UNLIMITED Words on all national outings. While other communications services can provide a basic review of your release, InvestorWire helps you do your best with Improved press release.

At our competitors, the job is done the second your exit goes on the wire. Not with InvestorWire. We include follow-up coverage of every release taking advantage of the ever-growing audience for the 50+ brands who make up the InvestorBrandNetwork.

Make the most of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please review the full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever posted or republished: Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, California 90046
310.299.1717 Office
[email protected]

InvestorWire is part of InvestorBrandNetwork.

Comments are closed.